Evidence map›Paper›PMID 37715448›Full record

ArticleJournal of diabetes investigation2023

Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.

Ryoichi Ishibashi, Kiichi Hirayama, Suzuka Watanabe, Kosuke Okano, Yuta Kuroda, Yusuke Baba, Takuma Kanayama, Chiho Ito, Keisuke Kasahara, Saki Aiba and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Ryoichi IshibashiDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.ORCID https://orcid.org/0000-0003-2535-5396
Kiichi HirayamaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Suzuka WatanabeDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Kosuke OkanoDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Yuta KurodaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Yusuke BabaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Takuma KanayamaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Chiho ItoDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Keisuke KasaharaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Saki AibaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Ryo IgaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Ryohei OhtaniDepartment of Medicine, Division of Neurology, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
Yosuke InabaClinical Research Center, Chiba University Hospital, Chiba, Japan.
Masaya KoshizakaDepartment of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.ORCID https://orcid.org/0000-0001-7374-9993
Yoshiro MaezawaDepartment of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Koutaro YokoteDepartment of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Kisarazu Hospital · JPChiba University · JPChiba University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial dysfunction causes maternally inherited deafness and diabetes (MIDD). Herein, we report improved glycemic control in a 47-year-old Japanese woman with MIDD using imeglimin without major adverse effects. Biochemical tests and metabolome analysis were performed before and after imeglimin administration. Blood glucose level fluctuations were determined. Sulfonylureas, dipeptidyl peptidase-4 inhibitors (DPP4is), and sodium glucose transporter-2 inhibitors (SGLT2i) were administered to evaluate the efficacy of their combination with imeglimin. Imeglimin decreased the HbA1c and ammonia levels and increased the time-in-range, C-peptide reactivity, and glucagon level. Elevated citrulline and histamine levels were decreased by imeglimin. The hypoglycemic effect was not enhanced by imeglimin when combined with sulfonylurea or DPP4i, but the blood glucose level was improved when combined with SGLT2i. Imeglimin improved glucose concentration-dependent insulin secretion and maximized the insulin secretory capacity by improving mitochondrial function and glutamine metabolism and urea circuit abnormalities by promoting glucagon secretion. Imeglimin could improve glycemic control in MIDD.

Indexed as

DeafnessDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsBlood GlucoseFemaleGlucagonGlycemic ControlHumansHypoglycemic AgentsMaternal InheritanceMiddle AgedTriazinesBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlucagonHypoglycemic AgentsimegliminSodium-Glucose Transporter 2 InhibitorsTriazinesImegliminMaternally inherited diabetes and deafnessMetabolome

Identifiers

PMID37715448
PMCPMC10688119
OpenAlexW4386796004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.